Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | HTR2B | P41595 | 4/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13235561 | 1.00 | GRM2 (0.33) | GRM2RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL13235542 | 0.96 | GRM2 (0.34) | GRM2RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL15445821 | 0.93 | RIPK1 (0.37) | GRM2RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL9562621 | 0.93 | RIPK1 (0.37) | GRM2RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL9562614 | 0.93 | RIPK1 (0.37) | GRM2RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL9562632 | 0.93 | RIPK1 (0.37) | GRM2RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL13235544 | 0.92 | GRM2 (0.33) | GRM2RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL13235564 | 0.92 | RIPK1 (0.35) | GRM2RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL2885443 | 0.92 | RIPK1 (0.35) | GRM2RIPK1HTR2CHTR2BHTR2A | |
| SCHEMBL2882945 | 0.92 | RIPK1 (0.35) | GRM2RIPK1HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7758931-B2 | Chlorofluorobenzene liquid crystal compound, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20090264683-A1 | CHLOROFLUOROBENZENE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7569258-B2 | Chlorofluorobenzene liquid crystal compound, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1873134-A1 | CHLOROFLUOROBENZENE LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264683-A1 | CHLOROFLUOROBENZENE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CCND3, CCND1, SLFN12 | GRM2 3559/4885RIPK1 1138/4885HTR2C 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.